SEC Filings

SEC Filings

10-K
PACIRA PHARMACEUTICALS, INC. filed this Form 10-K on 03/01/2017
Entire Document
 

PACIRA PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
 
Year Ended December 31,
 
2016
 
2015
 
2014
Revenues:
 
 
 
 
 
Net product sales
$
270,073

 
$
244,487

 
$
193,526

Collaborative licensing and milestone revenue
3,426

 
1,426

 
1,287

Royalty revenue
2,872

 
3,084

 
2,855

Total revenues
276,371

 
248,997

 
197,668

Operating expenses:
 
 
 
 
 
Cost of goods sold
110,104

 
71,837

 
77,440

Research and development
45,678

 
28,662

 
18,731

Selling, general and administrative
152,613

 
139,043

 
106,662

Total operating expenses
308,395

 
239,542

 
202,833

Income (loss) from operations
(32,024
)
 
9,455

 
(5,165
)
Other (expense) income:
 
 
 
 
 
Interest income
1,323

 
678

 
382

Interest expense
(7,061
)
 
(7,725
)
 
(8,278
)
Loss on early extinguishment of debt

 
(52
)
 

Royalty interest obligation

 
(71
)
 
(323
)
Other, net
(82
)
 
(165
)
 
(159
)
Total other expense, net
(5,820
)
 
(7,335
)
 
(8,378
)
Income (loss) before income taxes
(37,844
)
 
2,120

 
(13,543
)
Income tax expense
(105
)
 
(264
)
 
(173
)
Net income (loss)
$
(37,949
)
 
$
1,856

 
$
(13,716
)
 
 
 
 
 
 
Net income (loss) per share:
 
 
 
 
 
Basic net income (loss) per common share
$
(1.02
)
 
$
0.05

 
$
(0.39
)
Diluted net income (loss) per common share
$
(1.02
)
 
$
0.04

 
$
(0.39
)
Weighted average common shares outstanding:
 
 
 
 
 
Basic
37,236

 
36,540

 
35,299

Diluted
37,236

 
41,301

 
35,299

See accompanying notes to consolidated financial statements.

F- 5